PAHO

The state of the fight: 

U.S. regulators signed off on boosters for all adults.
  India raised a syringe export limit to allow supplies to reach PAHO and UNICEF.
  Pfizer will let Medicines Patent Pool sublicense its oral antiviral to manufacturers in 95 countries.

AUTHORIZED VACCINES  
 

Pfizer/BioNTech’s shot generated stronger antibody responses than three rival vaccines. Comirnaty’s performance bested those of the AstraZeneca/Oxford vaccine, the…

PAHO on Tuesday named Brazil’s Bio-Manguinhos and Argentina’s Sinergium Biotech as regional hubs for the development and production of mRNA-based vaccines in Latin America.

Reuters reported that the initiative—backed by Unitaid’s Medicines Patent Pool among others—seeks to “tap existing manufacturing capacities to help transfer vaccine technology developed by Moderna,” with an immediate emphasis on the Massachusetts-based company’s Covid-19 shot. WHO is also supporting a similar mRNA…

The state of the fight: 

Zydus Cadila’s three-dose, needle-free ZyCoV-D became the first authorized DNA-based Covid-19 vaccine.
  AstraZeneca’s AZD7442 long-acting antibody reduced infection risk by 77% in Phase 3.
  PAHO’s Revolving Fund will begin procuring Covid-19 vaccines for member states. Approved or authorized vaccines

 
Assessing antibody levels to predict Moderna’s effectiveness: Researchers at Seattle’s Fred Hutchinson Cancer Research Center announced…

The state of the hunt:

Moderna’s became the second Covid-19 vaccine to receive U.S. FDA Emergency Use Authorization.
  COVAX has secured nearly 2 billion doses of vaccines but faces a “very high” failure risk, according to Reuters.
  Canada, Saudi Arabia and the United States have begun immunization campaigns using Pfizer/BioNTech’s jab.

 

Vaccines


Approved or authorized vaccines
 
The U.S. FDA granted Emergency Use Authorization (EUA…

The state of the hunt:

Pfizer and BioNTech submitted a U.S. FDA Emergency Use Authorization request for their vaccine.
  Lilly’s rheumatoid arthritis drug Olumiant snagged an EUA (in combo with remdesivir) as a Covid-19 treatment.
  WHO formally issued a conditional recommendation against using Gilead’s remdesivir in hospitalized Covid-19 patients.

 

Vaccines


Phase 3 candidates

Pfizer/BioNTech request EUA: Friday’s submission to the U…

The state of the hunt:

With their mRNA vaccine showing an interim efficacy rate above 90%, Pfizer and BioNTech may have the necessary data to apply for U.S. FDA Emergency Use Authorization this month.
  Eli Lilly snagged the first FDA EUA for an anti-SARS-CoV-2 monoclonal antibody.
  Indonesia and Morocco laid out plans for Covid-19 mass immunization campaigns before year-end.

 

Vaccines


Phase 3 candidates:

Pfizer/BioNTech’s shot more…

Science Translational Medicine published a study last week showing that higher doses of benznidazole on a modified regimen eliminated Chagas disease in three mouse models—findings that challenge PAHO’s and WHO’s standard of care for the disease.

In lieu of the standard twice-daily, two-month regimen, University of Georgia researchers gave the animals a weekly dose (up to five times higher than the comparable daily dose) for 30 weeks. The treatment cleared infection and eliminated…

Mentions:

The state of the hunt:

Gavi made a preliminary deal with GSK and Sanofi, securing up to 200 million doses of their vaccine candidate for the COVAX Facility.
  British regulators began expedited reviews of vaccines from AstraZeneca and Pfizer, and South Korea also began an initial review of the AstraZeneca candidate.
  A trial of an investigational Lilly mAb failed against advanced Covid-19 cases, and a trial of a Regeneron mAb cocktail in people requiring high-flow…

A Pan American Health Organization (PAHO) study attributed a 75% reduction in chikungunya cases in sections of a Brazilian municipality to the introduction of Wolbachia-infected A. aegypti mosquitoes, PAHO announced last week, noting that the data are preliminary.

A PAHO team conducted the research in collaboration with the World Mosquito Program (WMP) and Fiocruz, comparing chikungunya incidence in parts of the city of Niterói where Wolbachia-carrying mosquitoes were released to…

Serum Institute of India (SII) announced at the end of December that WHO has prequalified its 10-valent pneumococcal conjugate vaccine (PCV).

A press release said the company aims to sell Pneumosil in low and middle-income countries for $2.00 per dose—one-third lower than competitors GSK and Pfizer currently offer to Gavi countries, and less than 20 percent of the multinationals’ price to PAHO countries.

SII said it has been able to lower manufacturing costs by including only the…

Mentions: